Harmony Biosciences Reiterates 2024 Net Product Revenue Guidance Of $700M - $720M, Est $710.288M
Portfolio Pulse from Benzinga Newsdesk
Harmony Biosciences has reiterated its 2024 net product revenue guidance of $700M - $720M, aligning with the estimated $710.288M. The company reported cash, cash equivalents, and investments of $434.1 million as of June 30, 2024, up from $425.6 million as of December 31, 2023.
August 06, 2024 | 11:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harmony Biosciences has reiterated its 2024 net product revenue guidance of $700M - $720M, aligning with the estimated $710.288M. The company also reported an increase in cash, cash equivalents, and investments to $434.1 million as of June 30, 2024.
Reiterating revenue guidance within the expected range and reporting an increase in cash and investments are positive indicators for Harmony Biosciences. This suggests financial stability and confidence in meeting revenue targets, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100